8-K: Tenax Therapeutics to Present Phase 3 Trial Data at ESC Congress

Tenax Therapeutics will present results from its Phase 3 LEVEL clinical trial at the European Society of Cardiology (ESC) Congress 2026, with topline data expected in August 2026.

Summary

• Tenax Therapeutics announced that results from its Phase 3 LEVEL clinical trial will be presented at the European Society of Cardiology (ESC) Congress 2026 in Munich, Germany, from August 28-31, 2026.
• The presentation will feature data on Levosimendan in patients with pulmonary hypertension due to heart failure with preserved ejection fraction (PH-HFpEF).
• The Company now expects to report topline data from the LEVEL clinical trial in August 2026, following the planned database lock and statistical analysis.
• Enrollment of over 230 patients in the LEVEL trial was completed in March 2026.
• A December 2025 analysis indicated the trial is powered at over 90% to detect a 25-meter change in 6-minute walk distance (6MWD), the primary endpoint.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive development, as the presentation of Phase 3 data at a major congress is a significant step towards potential market approval for a therapy addressing an unmet medical need.

Positives

• Results from the Phase 3 LEVEL clinical trial will be presented at a prestigious international congress (ESC Congress 2026).
• The trial is powered at well over 90% to detect a significant change in the primary endpoint (6MWD).
• Enrollment for the Phase 3 trial was completed ahead of schedule in March 2026.
• The company has global rights to develop and commercialize levosimendan for PH-HFpEF, a condition with no approved treatments.

Negatives

• Topline data from the Phase 3 LEVEL clinical trial is now expected in August 2026, a slight delay from potential presentation at ESC if data analysis was completed earlier.
• The company faces significant risks associated with clinical trials, regulatory review, and market acceptance of its product candidates.

Risks

• Risks associated with clinical trials, including timing, delays, costs, design, enrollment, and results.
• Delays in regulatory review and approval of product candidates.
• Uncertainty regarding market opportunity, formulation, production, marketing, customer acceptance, and clinical utility of product candidates.
• Reliance on third parties, including manufacturers and CROs.
• Potential volatility and uncertainty in the global economy and financial markets.
• Changes in legal, regulatory, and legislative environments impacting regulatory approval.
• Intellectual property risks.
• Cash needs and ability to fund operations.

Future Outlook

The company expects to report topline data from the Phase 3 LEVEL clinical trial in August 2026 and will present these results at the ESC Congress 2026. The company is developing levosimendan for PH-HFpEF, a condition for which no product is currently approved.

Management Comments

• Results from the Phase 3 LEVEL clinical trial will be presented in a Late-Breaking Clinical Science session at the European Society of Cardiology (ESC) Congress 2026.
• The Company now expects to report topline data from the Phase 3 LEVEL clinical trial in August 2026.
• In anticipation of potentially receiving topline results from the LEVEL clinical trial in time for presentation at ESC, an abstract was recently submitted.

Industry Context

StockSavvy.ai notes that the presentation of Phase 3 data at a major cardiology congress like ESC is a critical milestone for any pharmaceutical company developing a novel therapy. Success here could significantly de-risk the asset and pave the way for regulatory submissions, especially given the unmet need in PH-HFpEF.

Stakeholder Impact

• Shareholders: Potential positive impact if trial results are favorable, leading to increased valuation and future market approval.
• Patients: Potential future benefit from a new treatment option for PH-HFpEF, a condition with no current approved therapies.
• Healthcare Providers: Will receive new clinical data to inform treatment decisions for patients with PH-HFpEF.

Next Steps

• Present results from the Phase 3 LEVEL clinical trial at the ESC Congress 2026.
• Report topline data from the Phase 3 LEVEL clinical trial in August 2026.
• Proceed towards planned database lock and statistical analysis for the LEVEL trial.

Key Dates

Recommendation

The filing announces the presentation of Phase 3 data, which is a critical step. However, without the actual data results, a definitive recommendation cannot be made. Investors should await the topline data release and presentation to assess the trial's outcome before making investment decisions.

Keywords

Tenax Therapeutics, LEVEL trial, PH-HFpEF, Pulmonary Hypertension, Heart Failure, Levosimendan, ESC Congress 2026, Clinical Trial Data